{"filing":{"accession_number":"0001104659-26-092216","cik":"0001526119","ticker":"VSTM","company_name":"Verastem, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-06","primary_document":"tm2622452d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_8k.htm"},"events":[{"id":26062,"run_id":23672,"accession_number":"0001104659-26-092216","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Verastem entered into Amendment No. 3 to its Note Purchase Agreement on August 6, 2026, establishing a new series of Revenue Notes with an aggregate purchase price of up to $75 million, including an initial $50 million tranche to be issued on August 28, 2026, and an optional second $25 million tranche available through May 15, 2027.","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27060,"accession_number":"0001104659-26-092216","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Verastem entered into Amendment No. 3 to its Note Purchase Agreement on August 6, 2026, establishing a new series of \"Revenue Notes\" with an aggregate purchase price of up to $75 million. The amendment creates a material new direct financial obligation: an initial $50 million tranche of Revenue Notes to be issued on August 28, 2026, with an optional second $25 million tranche available through May 15, 2027. This constitutes creation of new debt securities and is a material capital-raising event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:03:05.934877+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27061,"accession_number":"0001104659-26-092216","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, which typically discloses material acquisitions, dispositions, or creation of direct financial obligations. The Item 2.03 heading explicitly addresses \"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.\" While the supplemental exhibit (EX-99.1) is a corporate presentation focused on clinical pipeline and commercial strategy rather than debt terms, the Item 2.03 disclosure structure and cross-reference to Item 1.01 strongly suggest a debt issuance or similar financial obligation was the triggering event, though the specific debt terms are not detailed in the provided excerpt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:03:05.934877+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26063,"run_id":23672,"accession_number":"0001104659-26-092216","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.85,"summary":"Verastem posted an updated corporate presentation on its website on August 6, 2026, disclosing it under Regulation FD, containing forward-looking statements about clinical trials, product development timelines, and market opportunities.","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27062,"accession_number":"0001104659-26-092216","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.85,"reasoning":"Verastem posted an updated corporate presentation on its website on August 6, 2026, disclosing it under Regulation FD. The presentation contains forward-looking statements about clinical trials, product development timelines, and market opportunities, but constitutes a routine disclosure of investor relations materials rather than a material event. While the presentation discusses ongoing clinical programs and pipeline milestones, the filing itself is a standard corporate communication tool that does not announce a new material event, transaction, or change in business status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:03:05.934877+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27060,"accession_number":"0001104659-26-092216","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Verastem entered into Amendment No. 3 to its Note Purchase Agreement on August 6, 2026, establishing a new series of \"Revenue Notes\" with an aggregate purchase price of up to $75 million. The amendment creates a material new direct financial obligation: an initial $50 million tranche of Revenue Notes to be issued on August 28, 2026, with an optional second $25 million tranche available through May 15, 2027. This constitutes creation of new debt securities and is a material capital-raising event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:03:05.934877+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-08-07"},{"id":27061,"accession_number":"0001104659-26-092216","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, which typically discloses material acquisitions, dispositions, or creation of direct financial obligations. The Item 2.03 heading explicitly addresses \"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.\" While the supplemental exhibit (EX-99.1) is a corporate presentation focused on clinical pipeline and commercial strategy rather than debt terms, the Item 2.03 disclosure structure and cross-reference to Item 1.01 strongly suggest a debt issuance or similar financial obligation was the triggering event, though the specific debt terms are not detailed in the provided excerpt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:03:05.934877+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-08-07"},{"id":27062,"accession_number":"0001104659-26-092216","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.85,"reasoning":"Verastem posted an updated corporate presentation on its website on August 6, 2026, disclosing it under Regulation FD. The presentation contains forward-looking statements about clinical trials, product development timelines, and market opportunities, but constitutes a routine disclosure of investor relations materials rather than a material event. While the presentation discusses ongoing clinical programs and pipeline milestones, the filing itself is a standard corporate communication tool that does not announce a new material event, transaction, or change in business status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:03:05.934877+00:00","company_name":"Verastem, Inc.","ticker":"VSTM","filing_date":"2026-08-07"}]}